Bavarian Nordic A/S (CPH:BAVA)
Denmark · Delayed Price · Currency is DKK | Market Cap | 18.46B |
| Revenue (ttm) | 6.46B |
| Net Income (ttm) | 1.42B |
| Shares Out | 77.86M |
| EPS (ttm) | 17.97 |
| PE Ratio | 13.20 |
| Forward PE | 17.99 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 310,349 |
| Average Volume | 306,636 |
| Open | 237.00 |
| Previous Close | 237.10 |
| Day's Range | 236.60 - 237.80 |
| 52-Week Range | 123.30 - 274.00 |
| Beta | 1.12 |
| RSI | 65.71 |
| Earnings Date | Aug 22, 2025 |
About Bavarian Nordic
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the Unite... [Read more]
Financial Performance
In 2024, Bavarian Nordic's revenue was 5.72 billion, a decrease of -19.06% compared to the previous year's 7.06 billion. Earnings were 987.98 million, a decrease of -33.03%.
Financial StatementsNews
Publication of statement by the Board of Directors in respect of the takeover offer to the shareholders of Bavarian Nordic from the consortium led by Nordic Capital and Permira
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Publication of offer document in respect of the takeover offer to the shareholders of Bavarian Nordic from the consortium led by Nordic Capital and Permira and lowering of minimum acceptance condition to 75%
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Bavarian Nordic AS (BVNKF) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ...
Bavarian Nordic AS (BVNKF) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic Market Expansions
Bavarian Nordic A/S 2025 Q2 - Results - Earnings Call Presentation
Bavarian Nordic A/S (BVNKF) Q2 2025 Earnings Call Transcript
Bavarian Nordic beats revenue expectations, as launch of takeover bid nears
Bavarian Nordic , subject of a takeover offer valuing the vaccine maker at about 19 billion Danish crowns ($3 billion), reported a higher than expected revenue for the second quarter on Friday, citing...
Bavarian Nordic (BVNKF) Reports Strong Revenue Growth in 1H 2024
Bavarian Nordic (BVNKF) Reports Strong Revenue Growth in 1H 2024
Bavarian Nordic A/S reports 1H results; updates FY outlook
Bavarian Nordic Announces First Half 2025 Results
COPENHAGEN, Denmark, August 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first half of 2025 and released its financial calenda...
Bavarian Nordic Announces Closing of Sale of Priority Review Voucher and Upgrades its 2025 Financial Guidance
COPENHAGEN, Denmark, July 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced the completion of the sale of its Priority Review Voucher (PRV). Upon completion, the company received a cash consi...
Bavarian Nordic agrees to $2.99B takeover by Permira and Nordic Capital
Bavarian Nordic Agrees to $2.99 Billion Private-Equity Takeover
Consortium led by Nordic Capital, Permira to acquire Bavarian Nordic
Vaccine maker Bavarian Nordic said on Monday it had entered into an agreement with Innosera ApS, a newly formed company controlled by a consortium led by Nordic Capital and Permira, which is to make a...
Consortium Led by Nordic Capital and Permira Will Make All-Cash Recommended Purchase Offer for Bavarian Nordic
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Bavarian Nordic climbs after buyout offer
Permira, Nordic in Takeover Talks for Vaccine Maker Bavarian
A consortium consisting of Nordic Capital and Permira is in talks for a potential takeover of Bavarian Nordic A/S, a Copenhagen-listed vaccine maker.
Bavarian Nordic in talks with Nordic Capital and Permira on potential takeover
Danish biotech Bavarian Nordic said on Thursday it is in discussions with a consortium of Nordic Capital and Permira regarding a potential takeover offer.
Rumours of a Potential Takeover Offer for Bavarian Nordic A/S
COPENHAGEN, Denmark, July 24, 2025 – Bavarian Nordic A/S (OMX: BAVA) has become aware of market rumours regarding a potential takeover offer for Bavarian Nordic A/S by a consortium consisting of Nordi...
Bavarian Nordic Receives Acceptance from Health Canada for Review of the New Drug Submission for its Chikungunya Vaccine
COPENHAGEN, Denmark, July 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company's application for licensure of the single-dose, virus-like p...
Bavarian Nordic Enters New Smallpox/Mpox Vaccine Supply Contract with European Country
COPENHAGEN, Denmark, July 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a contract valued over DKK 200 million to supply its MVA-BN® smallpox/mpox vaccine to a European countr...
Bavarian Nordic Announces the Initiation of Clinical Trials of Mpox Vaccine in Infants and Pregnant Women
COPENHAGEN, Denmark, June 26, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of the first of two clinical trials designed to support approval and use of the MVA-BN® mpox/smallpo...
Bavarian Nordic Initiates Phase 3 Study of Chikungunya Vaccine in Children
COPENHAGEN, Denmark, June 12, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a Phase 3 clinical study of its single-dose, virus-like particle (VLP) chikungunya vaccine, CHIKV...
Bavarian Nordic A/S (BVNKF) Q1 2025 Earnings Call Transcript
Bavarian Nordic A/S (OTCPK:BVNKF) Q1 2025 Earnings Conference Call May 9, 2025 8:00 AM ET Company Participants Rolf Sass Sorensen - Head, Investor Relations Paul Chaplin - Chief Executive Officer Henr...
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
COPENHAGEN, Denmark, May 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company's shares/related securities by persons holding manager...